SCREENING THE EFFECT OF VASICINE IN MULTIPLE SCLEROSIS USING HUMAN TISSUE CHIP MODEL

From time immemorial pharmacologists and researchers have always been in search for novel drug screening methods. One such unique technique that is gripping the world by its leash is “human tissue chip technology”. This study explores the creation of Multiple Sclerosis (MS) using human tissue chip and assessing the ability of Vasicine a quinazoline alkaloid derived from Adhatoda Justiciae plant in reversing the inflammatory pathology of multiple sclerosis. 10 ml of human peripheral blood was withdrawn using a sterile syringe from a healthy donor. The blood was centrifuged to obtain mesenchymal stem cells (MSC). Then the MSCs were transferred with Dulbecco’s Modified Eagle’s medium (DMEM). After 48 h incubation, the MSCs were transferred into four flasks with growth factors and were seeded into tissue chip for differentiation into neuronal cells, cardiomyocytes, hepatocytes, and skeletal muscle cells. The respective cells were dislodged from tissue chip for histopathological evaluation and differentiation confirmation. Lipopolysaccharide (LPS) was added to these cells, to mimic MS inflammation and was confined to histo-pathological assessment. 9 biomarkers specific for Multiple sclerosis was assessed using RTPCR and gel electrophoresis pre and post Vasicine treatment. After 48 h inflamed neuronal cells reverted 80% normal cell morphology with Vasicine treatment. These cells exhibited only 20% remnant inflammation. Hence Vasicine can be further explored as a prospective molecule to treat Multiple sclerosis and this tissue chip technique can be used effectively as a single platform for culturing four different types of cells simultaneously. Thus various toxicological and disease conditions can be assessed using the tissue chip.